Overview

With BaiPharm’s end-to-end support, another China-based biotech has successfully filed a U.S. FDA Type II Drug Master File (DMF) for its exosome product—strengthening compliance readiness and opening doors to global partnerships.

To date, BaiPharm has supported dozens of China-based companies with FDA DMF filings for exosome products, helping them accelerate international market entry. 

What Is a DMF?

A Drug Master File (DMF) is a confidential submission to the U.S. FDA that provides key Chemistry, Manufacturing, and Controls (CMC) information—covering facilities, processes, and quality systems. It enables NDA/ANDA sponsors to reference the data while protecting the holder’s proprietary know-how and helps the FDA evaluate manufacturing quality and safety.

Type II DMF typically covers drug substances (APIs), related intermediates, and materials used in their preparation. For exosome developers, a Type II DMF is often a practical prerequisite to qualify for U.S. supply chains and to support downstream regulatory submissions.

Note: A DMF is not a marketing authorization or “approval”; it is a referenced dossier that supports other FDA submissions.

Why Exosome Developers Prioritize DMF Filing?

Exosomes are advancing rapidly across regenerative medicine, diagnostics, and drug delivery. Given the FDA’s stringent requirements for biological products, not establishing a suitable DMF can lead to:

• Ineligibility to participate in U.S. supply chains and missed access to the world’s largest pharma market;

• Reduced ability to partner with U.S. pharmaceutical companies or medical institutions;

• Heightened compliance risk, including potential product detention or penalties.

Completing a Type II DMF not only demonstrates compliance readiness but also lays a foundation for future NDA/ANDA pathways—significantly enhancing market competitiveness.

BaiPharm’s DMF Filing Services

Pre-assessment and Compliance Diagnosis

• Comprehensive review of manufacturing processes, specifications, and safety data against Type II DMF expectations;

• Risk identification with targeted compliance improvement recommendations (e.g., facility upgrades, QC system strengthening). 

Technical Document Preparation

• Preparation of core DMF documents in accordance with the latest FDA guidelines: product description, process flow, quality control, stability, and safety assessment reports;

• Exosome-specific rigor for key attributes: isolation and purification process validation, particle size distribution control, and bioactivity testing methods. 

Submission & Review Follow-up

• Assistance with FDA Electronic Submissions Gateway (ESG) registration and document submission to ensure a smooth, error-free process;

• Real-time tracking of review status, management of FDA information requests, and coordinated data supplementation to keep timelines on track.

Post-filing Maintenance & Updates

• Support in establishing a DMF maintenance mechanism and submitting updates to the FDA in response to manufacturing changes or regulatory updates;

• Long-term compliance consulting to ensure continuous alignment with U.S. regulatory standards. 

Why Choose BaiPharm?

• Professional Team: Extensive FDA filing experience with a deep focus on biological product compliance, well-versed in exosome-specific technical and regulatory requirements.

• Efficient and Worry-free: One-stop end-to-end service that streamlines the entire filing process, allowing enterprises to focus on core business development.

• High Success Rate: Strict quality control over documentation and strategy optimization based on past successful cases.

• Tailored Strategies: Customized filing strategies based on each product’s characteristics and enterprise development stage.

Ready to Expand into the United States?

Contact us for professional, end-to-end regulatory support—so your exosome innovations can reach the global market with confidence.

About BaiPharm

BaiPharm, a wholly-owned subsidiary of REACH24H, specializes in pharmaceutical regulatory consulting and supply chain services. The team comprises seasoned experts in pharmacodynamics evaluation, drug development, regulatory affairs, and international business. BaiPharm offers market access services and post-marketing regulatory support for drug formulations, active pharmaceutical ingredients (APIs), excipients, and packaging materials.